Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DYNACIRC CR vs CADUET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.
Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.
Hypertension
Hypertension,Coronary artery disease,Hyperlipidemia (as adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels, and to increase HDL-C),Prevention of cardiovascular events in patients with multiple risk factors
Isradipine extended-release (Dyna Circ CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.
CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.
Terminal half-life approximately 7-8 hours; sustained due to controlled-release formulation.
Amlodipine: terminal half-life 30-50 h (enables once-daily dosing). Atorvastatin: terminal half-life ~14 h, but active metabolites (ortho- and para-hydroxy atorvastatin) have half-life 20-30 h; clinically, pharmacodynamic half-life (HMG-Co A reductase inhibition) is ~20-30 h.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Amlodipine: Extensively metabolized in the liver via CYP3A4 to inactive metabolites. Atorvastatin: Metabolized in the liver primarily by CYP3A4 to active ortho- and para-hydroxylated metabolites.
Primarily hepatic metabolism with biliary excretion; 20% renal, 80% fecal.
Amlodipine: 60% renal (metabolites), 20-25% biliary/fecal. Atorvastatin: 1% renal (unchanged), 90% biliary/fecal (≥70% as metabolites).
>95%, primarily to albumin and alpha-1 acid glycoprotein.
Amlodipine: ~93% bound to plasma proteins. Atorvastatin: ≥98% bound to plasma proteins (mainly albumin).
2.8 L/kg, indicating extensive tissue distribution.
Amlodipine: Vd ~21 L/kg (large, indicating extensive tissue distribution). Atorvastatin: Vd ~6.2 L/kg (moderately large, suggesting distribution into tissues).
Oral (CR): 20-30% due to first-pass metabolism.
Oral: amlodipine 64-90%; atorvastatin ~14% (low due to first-pass metabolism); food reduces rate but not extent of absorption.
For GFR <30 m L/min, start at 2.5 mg orally once daily; titrate cautiously. No adjustment necessary for GFR >=30 m L/min.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use atorvastatin with caution; maximum atorvastatin dose is 20 mg daily. Amlodipine is not dialyzable.
For Child-Pugh Class A or B: start at 2.5 mg orally once daily. For Child-Pugh Class C: avoid use due to lack of data.
Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. For Child-Pugh Class A or B hepatic impairment: atorvastatin dose should be reduced; maximum atorvastatin dose is 20 mg daily. Amlodipine clearance is decreased; initial amlodipine dose should be 2.5 mg daily. No data for Child-Pugh Class C; use contraindicated.
Safety and effectiveness in pediatric patients have not been established.
Not recommended for pediatric patients. Safety and efficacy in children <10 years have not been established. For patients 10-17 years with heterozygous familial hypercholesterolemia, atorvastatin monotherapy is used; CADUET is not indicated.
Initial dose: 2.5 mg orally once daily. Titrate slowly due to increased sensitivity and risk of hypotension.
Elderly patients (≥65 years) may have increased sensitivity to amlodipine; start at the lower end of dosing range (2.5 mg amlodipine component). Atorvastatin dose adjustment not required based on age alone. Monitor for hypotension and other adverse effects.
None
HMG-Co A reductase inhibitors (statins) can cause fetal harm; use in pregnant women is contraindicated. Caduet contains atorvastatin; therefore, it is contraindicated in pregnant women.
May cause hypotension, especially in volume-depleted patients,Peripheral edema,Hepatic impairment may require dose adjustment,May increase angina or myocardial infarction in patients with obstructive coronary disease upon initiation or dose escalation
Myopathy/Rhabdomyolysis: Risk increased with higher doses, age >65, renal impairment, hypothyroidism, and concurrent use of CYP3A4 inhibitors or other drugs that cause myopathy.,Hepatic effects: Elevated liver enzymes; perform liver function tests before initiation and as clinically indicated.,Fetal toxicity: May cause fetal harm; advise females of reproductive age to use effective contraception.,Peripheral edema: More common with higher doses of amlodipine, especially in females.,Hypotension: In patients with severe aortic stenosis.
Hypersensitivity to isradipine or any component,Cardiogenic shock,Acute myocardial infarction
Active liver disease or unexplained persistent elevations of hepatic transaminases,Pregnancy,Breastfeeding (due to potential for serious adverse reactions in nursing infants),Hypersensitivity to amlodipine, atorvastatin, or any component of the formulation
Grapefruit juice increases isradipine plasma concentrations; avoid concurrent use. High-fat meals may slightly delay absorption but no significant clinical effect.
Avoid grapefruit and grapefruit juice as they increase atorvastatin plasma concentrations and risk of adverse effects. No significant food interactions with amlodipine.
Isradipine (Dyna Circ CR) is a pregnancy category C drug. In animal studies, isradipine was not teratogenic in rats or rabbits at doses up to 150 mg/kg/day (approximately 100 times the maximum recommended human dose). However, embryotoxicity and fetotoxicity (increased resorptions, reduced fetal weight, delayed ossification) were observed at high doses. There are no adequate and well-controlled studies in pregnant women. Due to the potential risk of fetal harm, use only if the potential benefit justifies the risk. In the first trimester, avoid use if possible. In second and third trimesters, use with caution; may cause maternal hypotension and reduced uteroplacental perfusion.
FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-Co A reductase inhibitors are associated with fetal abnormalities, including skeletal and CNS defects. First trimester: Atorvastatin is contraindicated; risk of congenital anomalies. Second/third trimester: Avoid exposure; potential for fetal toxicity. Effective contraception required for women of childbearing potential.
Isradipine is excreted in human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.6. Limited data suggest that infant exposure is low. However, due to the potential for adverse effects in the nursing infant (e.g., hypotension, cardiovascular effects), caution should be exercised. Use only if clearly needed and monitor the infant for signs of hypotension or bradycardia.
Excreted in human milk: Amlodipine: present in low levels (M/P ratio approximately 1.0); atorvastatin: unknown. Due to potential for serious adverse reactions in nursing infants (e.g., skeletal muscle toxicity from statins), breastfeeding is contraindicated during therapy. Alternative agents preferred.
Pregnancy-induced pharmacokinetic changes (increased volume of distribution, increased renal clearance) may reduce isradipine concentrations. Empiric dose adjustment is not routinely recommended, but closer monitoring of blood pressure is advised. If inadequate response occurs, dose may be increased cautiously up to the maximum recommended dose (20 mg/day). No specific pregnancy dose adjustment guidelines exist; individualize therapy based on blood pressure response and tolerability.
Contraindicated during pregnancy; therefore, no dosing adjustments recommended. Discontinue therapy immediately if pregnancy is suspected or confirmed. Pharmacokinetic changes during pregnancy may alter drug metabolism, but no dose adjustments are justified due to teratogenic risk.
- DYNACIRC CR (isradipine controlled release) is a dihydropyridine calcium channel blocker used for hypertension. - The CR formulation allows once-daily dosing; avoid crushing or chewing tablets. - May cause dose-related peripheral edema, especially in higher doses or in elderly. - Use with caution in patients with aortic stenosis or in those with heart failure due to negative inotropic effects (though less than verapamil). - Grapefruit juice increases bioavailability; consider avoidance or dose adjustment. - Common side effects: headache, dizziness, flushing, and palpitations.
CADUET is a fixed-dose combination of amlodipine (a calcium channel blocker) and atorvastatin (a statin) used for hypertension and dyslipidemia. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) due to increased statin exposure and risk of myopathy. Monitor liver enzymes before and during therapy, and for muscle symptoms. Use with caution in patients with severe renal impairment. Avoid grapefruit juice as it increases atorvastatin levels.
Take exactly as prescribed once daily, preferably in the morning.,Swallow tablet whole; do not crush, chew, or split.,Avoid grapefruit juice while taking this medication.,Do not stop abruptly; may cause rebound hypertension.,Report persistent swelling in ankles/feet, palpitations, or severe dizziness.,May cause dizziness; avoid driving until you know how it affects you.
Take this medication once daily at the same time, with or without food.,Avoid grapefruit and grapefruit juice while taking this medication.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Notify your doctor if you become pregnant, plan to become pregnant, or are breastfeeding.,Do not stop taking this medication without consulting your doctor, even if you feel well.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DYNACIRC CR vs CADUET, answered by our medical review team.
DYNACIRC CR is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.. CADUET is a Calcium Channel Blocker + HMG-CoA Reductase Inhibitor that works by Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DYNACIRC CR and CADUET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DYNACIRC CR is: Isradipine extended-release (Dyna Circ CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.. The standard adult dose of CADUET is: CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DYNACIRC CR and CADUET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DYNACIRC CR is classified as Category C. Isradipine (DynaCirc CR) is a pregnancy category C drug. In animal studies, isradipine was not teratogenic in rats or rabbits at doses up to 150 mg/kg/day (approximately 100 times . CADUET is classified as Category C. FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-CoA reductase inhib. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.